GenSight Biologics, a clinical-stage biopharmaceutical company dedicated to developing innovative gene therapies for inherited retinal and neurodegenerative diseases, announced today that it has successfully raised nearly €1.7 million in a private fundraising round. The financing will support the company’s ongoing clinical development programs, strengthen working capital, and advance strategic objectives through 2026.

The financing round was led by GenSight Biologics’ existing major shareholders, including Advent France Biotechnology and RA Capital Management, with participation from a select group of institutional investors. The company emphasized that the transaction was completed without the involvement of underwriting or placement agents, highlighting strong investor confidence in its clinical strategy and operational execution.

The private placement involved the issuance of new shares at a price of €1.315 per share. Proceeds from the sale are expected to enhance the company’s liquidity and support key operational milestones, including ongoing regulatory interactions, dose optimization studies, and potential commercial planning activities.

“We are very pleased with the strong support from our existing investors, which underscores their confidence in GenSight Biologics’ vision and progress,” said a spokesperson of GenSight Biologics. “This funding provides critical resources to continue advancing our pipeline and brings us closer to delivering life-changing therapies for patients affected by inherited retinal and mitochondrial disorders.”

The funds will be allocated to advance GenSight Biologics’ pipeline of gene therapies, including GS010/LUMEVOQ, a therapy targeting Leber hereditary optic neuropathy (LHON) caused by mutations in the ND4 mitochondrial gene. Additionally, the financing will support the ongoing REVISE early-stage clinical study, which is evaluating optimal dose levels of the therapy.

GenSight Biologics is focused on pioneering gene therapies that address unmet medical needs in inherited retinal and neurodegenerative diseases. With this latest financing, the company is well-positioned to continue its clinical development programs, drive regulatory interactions, and pursue strategic growth initiatives over the next several years.

About GenSight Biologics
GenSight Biologics is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal and neurodegenerative diseases. The company’s lead programs focus on LHON and other mitochondrial disorders, aiming to restore or preserve vision and improve patient outcomes.